PDL BioPharma Inc. (PDLI) announced that it has entered into a non-exclusive license agreement with Eli Lilly and Co (LLY) under PDL's Queen et al patents with respect to teplizumab, as well as other potential next generation anti-CD3 molecules.
Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus.
Lilly currently holds a license to the Queen et al patents with respect to solanezumab.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.